What is Mbiomics?
Founded in 2020, Mbiomics operates at the intersection of biotechnology and advanced medical research. The company specializes in the development of microbiome-based therapeutics, leveraging proprietary platforms to identify and modulate microbial communities that influence human health. By focusing on the complex interactions within the gut microbiome, Mbiomics aims to address significant unmet medical needs in chronic disease management. Its strategic location in Munich allows it to tap into a robust network of academic research and industrial partnerships, positioning the company as a key player in the European life sciences landscape. The firm's commitment to rigorous scientific methodology and scalable therapeutic solutions has established it as a high-potential entity within the competitive biotech sector.
How much funding has Mbiomics raised?
Mbiomics has raised a total of $14.1M across 1 funding round:
Series A
$14.1M
Series A (2023): $14.1M with participation from High-Tech Gründerfonds, Bayern Kapital, and MIG
Key Investors in Mbiomics
High-Tech Gründerfonds
HTGF is a prominent pre-seed and seed investor specializing in high-tech startups, offering deep expertise in Life Sciences and Digital Tech to support founders from early stages through to potential IPOs.
Bayern Kapital
A leading venture capital firm in Bavaria, Bayern Kapital provides tailored financing solutions for technology-oriented startups, acting as a reliable anchor investor with a focus on sustainable innovation.
MIG
MIG is an architecture and engineering firm that brings a unique perspective to community-focused design and infrastructure development.
What's next for Mbiomics?
The recent strategic investment provides Mbiomics with the necessary runway to scale its operational capabilities and expand its clinical trial infrastructure. Moving forward, the company is expected to prioritize the optimization of its lead therapeutic candidates while strengthening its intellectual property portfolio. By leveraging the expertise of its institutional backers, Mbiomics will likely focus on establishing key partnerships with pharmaceutical entities to facilitate future drug development and commercialization pathways. As the company matures, the focus will shift toward demonstrating clinical efficacy and safety, which will be critical for securing subsequent growth-stage financing and achieving long-term market viability in the global biotech arena.
See full Mbiomics company page
